Evommune (EVMN) Total Current Liabilities (2024 - 2026)
Evommune (EVMN) posted quarterly Total Current Liabilities of $10.6 million for Q1 2026, down 40.8% quarter-over-quarter from $17.9 million in Q4 2025.
Evommune (EVMN) Total Current Liabilities (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Total Current Liabilities for 3 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $10.6 million (changed N/A YoY), while the FY2025 annual figure was $17.9 million, down 36.0% from the prior year.
- Total Current Liabilities eased to $10.6 million in Q1 2026 per EVMN's latest filing, from $17.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $28.0 million in Q4 2024 and bottomed at $10.4 million in Q3 2025.
- Historically, Total Current Liabilities has averaged $16.7 million across 3 years, with a median of $14.3 million in 2025.
- On a YoY basis, Total Current Liabilities climbed as much as 36.0% in 2025 and fell as far as 36.0% in 2025.
- Evommune's Total Current Liabilities stood at $28.0 million in 2024, then sank by 36.0% to $17.9 million in 2025, then plunged by 40.8% to $10.6 million in 2026.
- Business Quant data shows EVMN's Total Current Liabilities at $10.6 million in Q1 2026, $17.9 million in Q4 2025, and $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 17.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.49 Mn |
| Mar 31, 2026 | 10.60 Mn |
| Dec 31, 2025 | 17.91 Mn |
| Sep 30, 2025 | 10.42 Mn |
| Dec 31, 2024 | 27.98 Mn |